Simplified paper format for detecting HIV drug resistance in clinical specimens by oligonucleotide ligation

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Panpradist, Nuttada ^a   Beck, Ingrid A ^b   Chung, Michael H ^a   Kiarie, James N ^c   Frenkel, Lisa M ^a   Lutz, Barry R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGONUCLEOTIDE PROBE; POL PROTEIN;

ARTICLE; ASSAY; BLOOD ANALYSIS; CODON; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NUCLEIC ACID ANALYSIS; NUCLEIC ACID PROBE; OLIGONUCLEOTIDE LIGATION ASSAY; OLIGONUCLEOTIDE SURFACE CAPTURE DENATURATION AND DETECTION; POINT MUTATION; STRUCTURAL GENE; VIRUS DETECTION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRIED BLOOD SPOT TESTING; DRUG EFFECTS; ECONOMICS; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HIV INFECTIONS; KENYA; LIGASE CHAIN REACTION; MOLECULAR DIAGNOSIS; OLIGONUCLEOTIDE PROBE; PAPER; PROCEDURES; RETROSPECTIVE STUDY; SIGNAL NOISE RATIO; VIROLOGY;

ANTI-HIV AGENTS; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LIGASE CHAIN REACTION; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE PROBES; PAPER; POINT MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RETROSPECTIVE STUDIES; SIGNAL-TO-NOISE RATIO;

EID: 84954513070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145962     Document Type: Article

References (39)

1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-Lymphotropic retrovirus from a patient at risk for Acquired Immune Deficiency Syndrome (AIDS). Science. 1983; 220: 868-871. doi: 10.1126/science.6189183 PMID: 6189183
2. UNAIDS. HIV/AIDS Fact Sheet [Internet]. Geneva, Switzerland; 2012. Available: http://www.aids2014.org/webcontent/file/AIDS2014-Global-Factsheet-April-2014.pdf
3. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. Therapy in HIV-infected adults with CD4 cell counts. N Engl J Med. 1996; 335: 1081-1090. PMID: 8813038
4. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008; 197: 867-70. doi: 10.1086/528802 PMID: 18269317
5. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347: 385-94. doi: 10.1056/NEJMoa013552 PMID: 12167680
6. Jourdain G, Wagner TA, Ngo-giang-huong N, Klinbuayaem V, Fregonese F, Nantasen I, et al. Detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy is associated with virologic failure. Clin Infect Dis. 2011; 50: 1397-1404. doi: 10.1086/652148.detection
7. Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, Quinn JB, et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses. 2007; 23: 988-95. doi: 10.1089/aid.2006.0310 PMID: 17725415
8. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004; 351: 229-40. doi: 10.1056/NEJMoa041305 PMID: 15247339
9. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006; 43: 535-40. doi: 10.1097/01.qai.0000245886.51262.67 PMID: 17057609
10. Chung MH, Beck I a, Dross S, Tapia K, Kiarie JN, Richardson B a, et al. Oligonucleotide Ligation Assay Detects HIV Drug Resistance Associated with Virologic Failure among Antiretroviral-Naïve Adults in Kenya. J Acquir Immune Defic Syndr. 2014; 67: 246-253. doi: 10.1097/QAI.0000000000000312 PMID: 25140907
11. Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Rinke de Wit TF, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther. 2014; 11: 9. doi: 10.1186/1742-6405-11-9 PMID: 24456757
12. Thompson MA, Aberg JA, Hoy JF, Benson C, Gu HF, Hammer SM, et al. Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel. 2014; 308.
13. Günthard HF, Wong JK, Ignacio CC, Havlir D V, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998; 14: 869-76. PMID: 9671215
14. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005; 43: 406-13. doi: 10.1128/JCM.43.1.406-413.2005 PMID: 15635002
15. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007; 17: 1195-201. doi: 10.1101/gr.6468307 PMID: 17600086
16. Landegren U, Kaiser R, Sanders J, Hood L. A ligase-mediated gene detection technique. Science. 1988; 241: 1077-80. PMID: 3413476
17. Beck IA, Crowell C, Kittoe R, Bredell H, Machaba M, Willamson C, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008; 48: 418-27. doi: 10.1097/QAI. 0b013e31817ed7d7 PMID: 18614915
18. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1 pol Gene That Are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine. J Clin Microbiol. 1998; 36: 569-572. PMID: 9466779
19. Beck IA, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E, et al. Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations. J Clin Microbiol. 2002; 40: 1413-1419. doi: 10.1128/JCM.40.4.1413 PMID: 11923366
20. Beck I a, Deng W, Payant R, Hall R, Bumgarner RE, Mullins JI, et al. Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing. J Clin Microbiol. 2014; 52: 2320-7. doi: 10.1128/JCM.00306-14 PMID: 24740080
21. Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol. 2004; 42: 3670-3674. doi: 10.1128/JCM.42.8.3670 PMID: 15297515
22. Beck IA, Deng W, Payant R, Hall R, Bumgarner RE, Mullins JI, et al. Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing. J Clin Microbiol. 2014; 52: 2320-7. doi: 10.1128/JCM.00306-14 PMID: 24740080
23. Mutsvangwa J, Beck IA, Gwanzura L, Manhanzva MT, Chipato T, Frenkel LM. Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C. J Virol Methods. Elsevier B.V.; 2014; 210: 36-39. doi: 10.1016/j.jviromet.2014.09.005
24. Chung MH, Beck I a, Dross S, Tapia K, Kiarie JN, Richardson B a, et al. Oligonucleotide Ligation Assay Detects HIV Drug Resistance Associated with Virologic Failure among Antiretroviral-Naïve Adults in Kenya.-in press. PMID: 25140907. PMCID: PMC Journal-In Process (R01-AI058723 LMF, K23-AI065222 MHC, P30AI027757). J Acquir Immune Defic Syndr. 2014; doi: 10.1097/QAI. 0000000000000312
25. Fridley GE, Holstein CA, Oza SB, Yager P. The evolution of nitrocellulose as a material for bioassays. MRS Bull. Cambridge University Press; 2013; 38: 326-330. doi: 10.1557/mrs.2013.60
26. Josephygg PD, Elingg T, Mason P. The Horseradish Peroxidase-catalyzed Oxidation of 3,5,3′,5′- Tetramethylbenzidine. 1982; 257.
27. Awano H, Ichihara O, Sawada K, Ohigashi H. Highly dimerizable radical cation of 3,3′,5,5′-tetramethylbenzidine. Berichte der Bunsengesellschaft für Phys Chemie. 1996; 100: 1700-1705. doi: 10.1002/bbpc.19961001006
28. Herzog V, Fahimi HD. A new sensitive colorimetric assay for peroxidase using 3,3′-diaminobenzidine as hydrogen donor. Anal Biochem. 1973; 55: 554-562. doi: 10.1016/0003-2697(73)90144-9 PMID: 4750690
29. Wagner TA, Kress CM, Beck I, Techapornroong M, Wittayapraparat P, Tansuphasawasdikul S, et al. Detection of HIV-1 drug resistance in women following administration of a single dose ofnevirapine : comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide Ligation Assay. J Clin Microbiol. 2010; 48: 1555-1561. doi: 10.1128/JCM.02062-09 PMID: 20181911
30. Ramachandran S, Peltier J, Osborn J, Holstein C, Lutz BR, Fu E, et al. Integrated assay and sample processing: paper-based device for IgM detection. The 16 th International conference on minaturised systems for chemistry and life sciences (μTAS). Okinawa, Japan; 2012.
31. Fridley GE, Le HQ, Fu E, Yager P. Controlled release of dry reagents in porous media for tunable temporal and spatial distribution upon rehydration. Lab Chip. The Royal Society of Chemistry; 2012; 12: 4321-7. doi: 10.1039/c2lc40785j PMID: 22960691
32. Ramachandran S, Fu E, Lutz BR, Yager P. Long-term dry storage of an enzyme-based reagent system for ELISA in point-of-care devices. Anal-London-Soc Public Anal then R Soc Chem. 2014; 139: 1456-1462.
33. Montoya A, Castell J V. Long-term storage of peroxidase-labelled immunoglobulins for use in enzyme immunoassay. J Immunol Methods. 1987; 99: 13-20. PMID: 3033084
34. Altikatoglu M, Basaran Y. Additive effect of dextrans on the stability of horseradish peroxidase. Protein J. 2011; 30: 84-90. doi: 10.1007/s10930-011-9306-4 PMID: 21243417
35. Lutz BR, Liang T, Fu E, Ramachandran S, Kauffman P, Yager P. Dissolvable fluidic time delays for programming multi-step assays in instrument-free paper diagnostics. Lab Chip. The Royal Society of Chemistry; 2013; 13: 2840-7. doi: 10.1039/c3lc50178g PMID: 23685876
36. Toley BJ, McKenzie B, Liang T, Buser JR, Yager P, Fu E. Tunable-delay shunts for paper microfluidic devices. Anal Chem. 2013; 85: 11545-52. doi: 10.1021/ac4030939 PMID: 24245747
37. Toley BJ, Fu E, Yager P. A powerless valving system for fluific flow in paper networks. 16th International Conference on Miniaturized Systems for Chemistry and Life Sciences. Okinawa, Japan; 2012. pp. 305-307.
38. Dharmaraja S, Lafleur L, Byrnes S, Kauffman P, Buser J, Toley B, et al. Programming paper networks for point of care diagnostics. Proceedings of SPIE, 8615, Microfluidics, BioMEMS, and Medical Microsystem XI. 2013. doi: 10.1117/12.2006138
39. Lutz BR, Trinh P, Ball C, Fu E, Yager P. Two-dimensional paper networks: programmable fluidic disconnects for multi-step processes in shaped paper. Lab Chip. The Royal Society of Chemistry; 2011; 11: 4274-8. doi: 10.1039/c1lc20758j PMID: 22037591